数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Walter V. Klemp Chairman of the Board, President and Chief Executive Officer 61 151.68万美元 未持股 2021-03-06
Robert E. George Director 70 8.02万美元 未持股 2021-03-06
Michael D. Cannon Director 75 7.39万美元 未持股 2021-03-06
Elizabeth A. Cermak Director 63 4.23万美元 未持股 2021-03-06
John M. Climaco Director 52 8.40万美元 未持股 2021-03-06

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Walter V. Klemp Chairman of the Board, President and Chief Executive Officer 61 151.68万美元 未持股 2021-03-06
Donald Picker Chief Scientific Officer 75 52.03万美元 未持股 2021-03-06
Robert Shepard Chief Medical Officer - Annamycin 68 未披露 未持股 2021-03-06
Sandra L. Silberman Chief Medical Officer - New Products 66 未披露 未持股 2021-03-06
Jonathan P. Foster Chief Financial Officer and Executive Vice President 57 94.66万美元 未持股 2021-03-06

董事简历

中英对照 |  中文 |  英文
Walter V. Klemp

Walter V. Klemp,我公司联合创始人,自2015年7月起担任董事长兼临时首席执行官;自2006年起担任Moleculin LLC的董事长、联合创始人兼兼职首席执行官;自2011年11月起担任Soliton, Inc.(医疗设备公司,关注开发应用于美学的新技术)的首席执行官;2004年至2011年4月间担任Zeno Corporation的总裁兼首席执行官,开发并营销皮肤病设备和药物,参与从其概念到新药审核并投入市场的整个过程;1987年至2000年间担任Drypers Corporation(上市跨国公司,主营消费者产品,在美国成长最快的企业INC 500榜单中位列第一)的首席执行官兼董事长。


Walter V. Klemp is a co-founder of our company, and has served as our chairman of the board and chief executive officer since July 2015 and as president since August 2017. Since July 2018 Mr. Klemp has served as executive chairman on the board of directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics. From November 2011 to July 2018 Mr. Klemp served as chief executive officer of Soliton. Mr. Klemp served as president and chief executive officer of Zeno Corporation from 2004 to April 2011 where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch. From 1987 to 2000 Mr. Klemp served as chief executive officer and chairman of Drypers Corporation, a publicly traded multinational consumer products company that was listed as #1 on the INC 500 List of America’s Fastest Growing Companies.
Walter V. Klemp,我公司联合创始人,自2015年7月起担任董事长兼临时首席执行官;自2006年起担任Moleculin LLC的董事长、联合创始人兼兼职首席执行官;自2011年11月起担任Soliton, Inc.(医疗设备公司,关注开发应用于美学的新技术)的首席执行官;2004年至2011年4月间担任Zeno Corporation的总裁兼首席执行官,开发并营销皮肤病设备和药物,参与从其概念到新药审核并投入市场的整个过程;1987年至2000年间担任Drypers Corporation(上市跨国公司,主营消费者产品,在美国成长最快的企业INC 500榜单中位列第一)的首席执行官兼董事长。
Walter V. Klemp is a co-founder of our company, and has served as our chairman of the board and chief executive officer since July 2015 and as president since August 2017. Since July 2018 Mr. Klemp has served as executive chairman on the board of directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics. From November 2011 to July 2018 Mr. Klemp served as chief executive officer of Soliton. Mr. Klemp served as president and chief executive officer of Zeno Corporation from 2004 to April 2011 where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch. From 1987 to 2000 Mr. Klemp served as chief executive officer and chairman of Drypers Corporation, a publicly traded multinational consumer products company that was listed as #1 on the INC 500 List of America’s Fastest Growing Companies.
Robert E. George

RobertE.George在首次公开募股时加入了我们的董事会。他曾担任普华永道会计师事务所(PricewaterhouseCoopers PwC)的国际会计公司的合伙人27年,直到2010年,在那里他的客户服务部门包括梦百合等。George先生目前担任休斯顿德克萨斯大学健康科学中心(University of Texas Health Science Center at Houston)的审计委员会主席,并自2011年6月起担任德克萨斯大学奥斯汀分校McCombs商业会计研究生院的成员。George先生在北德克萨斯大学(University of North Texas)获得会计学B.B.A.(优等生)。


Robert E. George joined our board of directors upon our IPO. He was a partner with the international accounting firm of PricewaterhouseCoopers PWC for 27 years until 2010 where his client service sectors included healthcare, among others. Mr. George currently serves as Chairman of the Audit Committee for The University of Texas Health Science Center at Houston and, since June 2011 has been a member of The University of Texas at Austin, McCombs Graduate School of Business accounting faculty. Mr. George has a B.B.A. - Accounting (cum laude) from the University of North Texas.
RobertE.George在首次公开募股时加入了我们的董事会。他曾担任普华永道会计师事务所(PricewaterhouseCoopers PwC)的国际会计公司的合伙人27年,直到2010年,在那里他的客户服务部门包括梦百合等。George先生目前担任休斯顿德克萨斯大学健康科学中心(University of Texas Health Science Center at Houston)的审计委员会主席,并自2011年6月起担任德克萨斯大学奥斯汀分校McCombs商业会计研究生院的成员。George先生在北德克萨斯大学(University of North Texas)获得会计学B.B.A.(优等生)。
Robert E. George joined our board of directors upon our IPO. He was a partner with the international accounting firm of PricewaterhouseCoopers PWC for 27 years until 2010 where his client service sectors included healthcare, among others. Mr. George currently serves as Chairman of the Audit Committee for The University of Texas Health Science Center at Houston and, since June 2011 has been a member of The University of Texas at Austin, McCombs Graduate School of Business accounting faculty. Mr. George has a B.B.A. - Accounting (cum laude) from the University of North Texas.
Michael D. Cannon

MichaelD.Cannon在首次公开募股时加入了我们的董事会。Cannon从1997年到2004年担任Sicor,Inc.(一家美国公共制药公司)执行副总裁和董事,直到该公司被Teva Pharmaceutical Industries,Inc.收购。SICOR专注于仿制药成品剂量注射药物,活性药物成分和仿制药。任职Sicor公司期间,他曾监管生物业务的收购和发展,包括国际合作伙伴关系的发起和管理,以及蛋白质制造设施的设计、建设和许可。Cannon从2005年7月到2009年12月担任Trevi Health Ventures LP(一家纽约投资基金,专门从事医疗保健投资)科学顾问委员会成员。从2005年5月到2011年12月,Cannon先生是一个私人合伙企业的合伙人,该合伙企业的成立是为了评估和执行梦百合部门知识产权的初步开发。Cannon先生从2005年开始担任多家私人公司的董事会成员。Cannon先生目前任职于三家私人持有的生物技术公司的董事会。他曾任职于纳斯达克上市公司Athenex,Inc.的董事会。Cannon先生拥有Fordham College的化学学位。


Michael D. Cannon joined our board of directors upon our IPO. Between 1997 and 2004 Mr. Cannon was the Chief Science Officer, EVP and a Director of SICOR, Inc., a U.S. public pharmaceutical company, until its acquisition by Teva Pharmaceutical Industries, Inc. SICOR focused on generic finished dosage injectable pharmaceuticals, active pharmaceutical ingredients and generic biopharmaceuticals. While at SICOR, he oversaw the acquisition and development of the biological business, including initiation and management of international partnerships, as well as on the design, construction, and licensure of protein manufacturing facilities. From July 2005 to December 2009 Mr. Cannon was a member of the scientific advisory board of Trevi Health Ventures LP, a New York investment fund specializing in health care investments. From May 2005 until December 2011 Mr. Cannon was a partner in a private partnership formed to evaluate and perform preliminary development of intellectual property in the healthcare sector. Since 2005 Mr. Cannon has served as a board member for several private companies. Mr. Cannon currently serves on the boards of directors of three privately held biotech companies. He previously served on the board of directors of Athenex, Inc., a public company traded on the NASDAQ. Mr. Cannon has a degree in chemistry from Fordham College.
MichaelD.Cannon在首次公开募股时加入了我们的董事会。Cannon从1997年到2004年担任Sicor,Inc.(一家美国公共制药公司)执行副总裁和董事,直到该公司被Teva Pharmaceutical Industries,Inc.收购。SICOR专注于仿制药成品剂量注射药物,活性药物成分和仿制药。任职Sicor公司期间,他曾监管生物业务的收购和发展,包括国际合作伙伴关系的发起和管理,以及蛋白质制造设施的设计、建设和许可。Cannon从2005年7月到2009年12月担任Trevi Health Ventures LP(一家纽约投资基金,专门从事医疗保健投资)科学顾问委员会成员。从2005年5月到2011年12月,Cannon先生是一个私人合伙企业的合伙人,该合伙企业的成立是为了评估和执行梦百合部门知识产权的初步开发。Cannon先生从2005年开始担任多家私人公司的董事会成员。Cannon先生目前任职于三家私人持有的生物技术公司的董事会。他曾任职于纳斯达克上市公司Athenex,Inc.的董事会。Cannon先生拥有Fordham College的化学学位。
Michael D. Cannon joined our board of directors upon our IPO. Between 1997 and 2004 Mr. Cannon was the Chief Science Officer, EVP and a Director of SICOR, Inc., a U.S. public pharmaceutical company, until its acquisition by Teva Pharmaceutical Industries, Inc. SICOR focused on generic finished dosage injectable pharmaceuticals, active pharmaceutical ingredients and generic biopharmaceuticals. While at SICOR, he oversaw the acquisition and development of the biological business, including initiation and management of international partnerships, as well as on the design, construction, and licensure of protein manufacturing facilities. From July 2005 to December 2009 Mr. Cannon was a member of the scientific advisory board of Trevi Health Ventures LP, a New York investment fund specializing in health care investments. From May 2005 until December 2011 Mr. Cannon was a partner in a private partnership formed to evaluate and perform preliminary development of intellectual property in the healthcare sector. Since 2005 Mr. Cannon has served as a board member for several private companies. Mr. Cannon currently serves on the boards of directors of three privately held biotech companies. He previously served on the board of directors of Athenex, Inc., a public company traded on the NASDAQ. Mr. Cannon has a degree in chemistry from Fordham College.
Elizabeth A. Cermak

Elizabeth A. Cermak,自2009年加入POZEN担任执行副总裁和首席商务官。在加入POZEN之前,即2006年她担任Johnson and Johnson的消费者健康部门的世界范围内副总裁。2005年她是McNeil Consumer and Specialty股份有限公司业务拓展副总裁,2003-2005年是Ortho-McNeil Pharmaceuticals股份有限公司女性健康特许副总裁。她在医疗保健行业花了25年的时间并带领许多营销和销售组织。她拥有Drexel大学(位于宾夕法尼亚州费城(Philadelphia, PA))财务专业的工商管理硕士学位和Franklin and Marshall学院(位于宾夕法尼亚州费城(Philadelphia, PA))会计学士学位。


Elizabeth A. Cermak joined our board of directors in October 2020. Ms. Cermak has held numerous board positions in the healthcare space, including currently at both Que Oncology and Clarus Therapeutics, Inc., where she serves as an Independent Board Director. In addition, Ms. Cermak was formerly an Independent Board Director at SteadyMed Therapeutics. From 2009 to 2013 Ms. Cermak was the Chief Commercial Officer and Executive Vice President at POZEN, now Aralez Pharmaceuticals. As Chief Commercial Officer at POZEN, Ms. Cermak developed the commercial strategy and launch Plans for the Company's first self-marketed product, and signed licensing deals with Johnson & Johnson, Desitin, and Sanofi. Prior to joining POZEN, Ms. Cermak worked at Johnson & Johnson for 25 years, serving most recently as World-Wide Vice President Personal Products Franchise and Vice President Professional Sales & Marketing.
Elizabeth A. Cermak,自2009年加入POZEN担任执行副总裁和首席商务官。在加入POZEN之前,即2006年她担任Johnson and Johnson的消费者健康部门的世界范围内副总裁。2005年她是McNeil Consumer and Specialty股份有限公司业务拓展副总裁,2003-2005年是Ortho-McNeil Pharmaceuticals股份有限公司女性健康特许副总裁。她在医疗保健行业花了25年的时间并带领许多营销和销售组织。她拥有Drexel大学(位于宾夕法尼亚州费城(Philadelphia, PA))财务专业的工商管理硕士学位和Franklin and Marshall学院(位于宾夕法尼亚州费城(Philadelphia, PA))会计学士学位。
Elizabeth A. Cermak joined our board of directors in October 2020. Ms. Cermak has held numerous board positions in the healthcare space, including currently at both Que Oncology and Clarus Therapeutics, Inc., where she serves as an Independent Board Director. In addition, Ms. Cermak was formerly an Independent Board Director at SteadyMed Therapeutics. From 2009 to 2013 Ms. Cermak was the Chief Commercial Officer and Executive Vice President at POZEN, now Aralez Pharmaceuticals. As Chief Commercial Officer at POZEN, Ms. Cermak developed the commercial strategy and launch Plans for the Company's first self-marketed product, and signed licensing deals with Johnson & Johnson, Desitin, and Sanofi. Prior to joining POZEN, Ms. Cermak worked at Johnson & Johnson for 25 years, serving most recently as World-Wide Vice President Personal Products Franchise and Vice President Professional Sales & Marketing.
John M. Climaco

John M. Climaco, 他是一名法律博士,也是一位经验丰富而且成就突出的企业行政管理人员、董事和律师,并且具备15年在上市公司和私营企业任职的企业管理和企业战略经验。自2012年12月,他在Digirad 公司担任董事。自2013年12月,他在PDI公司任职。PDI公司是一家外包销售和营销的上市公司。自2013年10月,他在Perma Fix Environmental Solutions公司任职。Perma Fix Environmental Solutions公司是一家上市公司,致力于解决环境问题并开展相关业务。自2012年4月至2013年4月,他在InfuSystem Holdings公司任职。InfuSystem Holdings公司是一家提供医疗设备和服务的上市公司。他在Axial Biotech公司担任总裁、首席执行官和董事。Axial Biotech公司是他于2003年1月与他人共同创办的公司。该公司是一家采用分子诊断技术以治疗脊椎病的风险投资公司。作为Axial Biotech公司的总裁和首席执行官,他把基因药学带入整形外科领域。Axial Biotech公司还开发并推广了ScoliScore,利用多基因测试方法来判定患有脊柱侧凸症状儿童的脊柱侧弯度发展的可能性。通过产品开发和国际推广手段,他引领Axial公司从开端到发展,他还筹集了3000万美元的风险资本,并和Medtronic公司、Johnson & Johnson 公司和 Smith & Nephew这三家公司确立了合作伙伴关系。在与他人建立Axial公司前,即自1997年至2003年,他在Fabian & Clendenin公司进行律师事务的实习。他在米德尔伯里学院(Middlebury College)以优异成绩获得学士学位,并在加利福尼亚大学黑斯廷斯法学院(University of California, Hastings College of La)获得法学博士学位。


John M. Climaco,joined CNS in September 2017 as its Chief Executive Officer. Mr. Climaco has served in leadership roles in a variety of healthcare companies. From April 2015 to June 2017 Mr. Climaco served as the Executive Vice-President of Perma-Fix Medical S.A where he managed the development of a novel method to produce Technitium-99. Mr. Climaco also served as President and CEO of Axial Biotech, Inc., a DNA diagnostics company, from January 2003 to January 2013. In the process of taking Axial from inception to product development to commercialization, Mr. Climaco created strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew. Mr. Climaco currently serves as a director of several public companies including Moleculin Biotech, Inc., a pharmaceutical company focused on anticancer drug candidates, where he has served since May 2017. Mr. Climaco served on the boards of Digirad, Inc., a leading national provider of imaging services, from May 2012 until April 2020, and Birner Dental Management Services, Inc., a provider of practice management services in the dental industry, since June 2017. Mr. Climaco also served as a director of PDI, Inc., a provider of outsourced commercial services to pharma companies, in 2015, and InfuSystem Holdings, Inc., the largest supplier of infusion services to oncologists in the U.S., from April 2012 to April 2014. Mr. Climaco obtained his Juris Doctorate Degree from the University of California Hastings College of Law in San Francisco, CA in January 2000 and a Bachelor of Philosophy from Middlebury College in Middlebury, VT, in May 1991. Mr. Climaco is active with the State Bar of Utah.
John M. Climaco, 他是一名法律博士,也是一位经验丰富而且成就突出的企业行政管理人员、董事和律师,并且具备15年在上市公司和私营企业任职的企业管理和企业战略经验。自2012年12月,他在Digirad 公司担任董事。自2013年12月,他在PDI公司任职。PDI公司是一家外包销售和营销的上市公司。自2013年10月,他在Perma Fix Environmental Solutions公司任职。Perma Fix Environmental Solutions公司是一家上市公司,致力于解决环境问题并开展相关业务。自2012年4月至2013年4月,他在InfuSystem Holdings公司任职。InfuSystem Holdings公司是一家提供医疗设备和服务的上市公司。他在Axial Biotech公司担任总裁、首席执行官和董事。Axial Biotech公司是他于2003年1月与他人共同创办的公司。该公司是一家采用分子诊断技术以治疗脊椎病的风险投资公司。作为Axial Biotech公司的总裁和首席执行官,他把基因药学带入整形外科领域。Axial Biotech公司还开发并推广了ScoliScore,利用多基因测试方法来判定患有脊柱侧凸症状儿童的脊柱侧弯度发展的可能性。通过产品开发和国际推广手段,他引领Axial公司从开端到发展,他还筹集了3000万美元的风险资本,并和Medtronic公司、Johnson & Johnson 公司和 Smith & Nephew这三家公司确立了合作伙伴关系。在与他人建立Axial公司前,即自1997年至2003年,他在Fabian & Clendenin公司进行律师事务的实习。他在米德尔伯里学院(Middlebury College)以优异成绩获得学士学位,并在加利福尼亚大学黑斯廷斯法学院(University of California, Hastings College of La)获得法学博士学位。
John M. Climaco,joined CNS in September 2017 as its Chief Executive Officer. Mr. Climaco has served in leadership roles in a variety of healthcare companies. From April 2015 to June 2017 Mr. Climaco served as the Executive Vice-President of Perma-Fix Medical S.A where he managed the development of a novel method to produce Technitium-99. Mr. Climaco also served as President and CEO of Axial Biotech, Inc., a DNA diagnostics company, from January 2003 to January 2013. In the process of taking Axial from inception to product development to commercialization, Mr. Climaco created strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew. Mr. Climaco currently serves as a director of several public companies including Moleculin Biotech, Inc., a pharmaceutical company focused on anticancer drug candidates, where he has served since May 2017. Mr. Climaco served on the boards of Digirad, Inc., a leading national provider of imaging services, from May 2012 until April 2020, and Birner Dental Management Services, Inc., a provider of practice management services in the dental industry, since June 2017. Mr. Climaco also served as a director of PDI, Inc., a provider of outsourced commercial services to pharma companies, in 2015, and InfuSystem Holdings, Inc., the largest supplier of infusion services to oncologists in the U.S., from April 2012 to April 2014. Mr. Climaco obtained his Juris Doctorate Degree from the University of California Hastings College of Law in San Francisco, CA in January 2000 and a Bachelor of Philosophy from Middlebury College in Middlebury, VT, in May 1991. Mr. Climaco is active with the State Bar of Utah.

高管简历

中英对照 |  中文 |  英文
Walter V. Klemp

Walter V. Klemp,我公司联合创始人,自2015年7月起担任董事长兼临时首席执行官;自2006年起担任Moleculin LLC的董事长、联合创始人兼兼职首席执行官;自2011年11月起担任Soliton, Inc.(医疗设备公司,关注开发应用于美学的新技术)的首席执行官;2004年至2011年4月间担任Zeno Corporation的总裁兼首席执行官,开发并营销皮肤病设备和药物,参与从其概念到新药审核并投入市场的整个过程;1987年至2000年间担任Drypers Corporation(上市跨国公司,主营消费者产品,在美国成长最快的企业INC 500榜单中位列第一)的首席执行官兼董事长。


Walter V. Klemp is a co-founder of our company, and has served as our chairman of the board and chief executive officer since July 2015 and as president since August 2017. Since July 2018 Mr. Klemp has served as executive chairman on the board of directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics. From November 2011 to July 2018 Mr. Klemp served as chief executive officer of Soliton. Mr. Klemp served as president and chief executive officer of Zeno Corporation from 2004 to April 2011 where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch. From 1987 to 2000 Mr. Klemp served as chief executive officer and chairman of Drypers Corporation, a publicly traded multinational consumer products company that was listed as #1 on the INC 500 List of America’s Fastest Growing Companies.
Walter V. Klemp,我公司联合创始人,自2015年7月起担任董事长兼临时首席执行官;自2006年起担任Moleculin LLC的董事长、联合创始人兼兼职首席执行官;自2011年11月起担任Soliton, Inc.(医疗设备公司,关注开发应用于美学的新技术)的首席执行官;2004年至2011年4月间担任Zeno Corporation的总裁兼首席执行官,开发并营销皮肤病设备和药物,参与从其概念到新药审核并投入市场的整个过程;1987年至2000年间担任Drypers Corporation(上市跨国公司,主营消费者产品,在美国成长最快的企业INC 500榜单中位列第一)的首席执行官兼董事长。
Walter V. Klemp is a co-founder of our company, and has served as our chairman of the board and chief executive officer since July 2015 and as president since August 2017. Since July 2018 Mr. Klemp has served as executive chairman on the board of directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics. From November 2011 to July 2018 Mr. Klemp served as chief executive officer of Soliton. Mr. Klemp served as president and chief executive officer of Zeno Corporation from 2004 to April 2011 where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch. From 1987 to 2000 Mr. Klemp served as chief executive officer and chairman of Drypers Corporation, a publicly traded multinational consumer products company that was listed as #1 on the INC 500 List of America’s Fastest Growing Companies.
Donald Picker

Donald Picker,2007年加入Moleculin,担任首席执行官,自2015年7月起担任首席运营官,2016年1月起担任总裁;2007年成为IntertechBio的首席执行官;2006年至2007年间担任Tapestry Pharmaceuticals的总裁;1998年至2003年间担任Synergy Pharmaceuticals的首席执行官,该公司已与Callisto Pharmaceuticals合并,而他在后者担任研发副总裁直至2006年。他领导研发卡铂(carboplatin)和顺铂(cisplatin)从概念到通过新药审核。这些药物一通过审核便被用于首选化疗药物。他获得了Brooklyn Polytechnic University的学士学位,1975年获得SUNY Albany的博士学位。


Donald Picker,has served as Cns Pharmaceuticals, Inc. part-time chief science officer since June 2019. Dr. Picker has served as the chief scientific officer of Moleculin Biotech, Inc. since August 2017 after serving as its chief operating officer from July 2015 until August 2017 and as its president from January 2016 to August 2017. In 2007, Dr. Picker became the chief executive officer of IntertechBio Corp. From 2006 through 2007, Dr. Picker was the President of Tapestry Pharmaceuticals. From 1998 to 2003, Dr. Picker was CEO of Synergy Pharmaceuticals. Synergy was merged into Callisto Pharmaceuticals where he was vice present of research and development until 2006. From 2017 to 2018, Dr. Picker served on Cns Pharmaceuticals, Inc. board of directors. Dr. Picker received his B.S. degree from Brooklyn Polytechnic University and his PhD from SUNY Albany in 1975. Dr. Picker is currently devoting only 25% of his work time to Cns Pharmaceuticals, Inc. and provides services as needed to Cns Pharmaceuticals, Inc. .
Donald Picker,2007年加入Moleculin,担任首席执行官,自2015年7月起担任首席运营官,2016年1月起担任总裁;2007年成为IntertechBio的首席执行官;2006年至2007年间担任Tapestry Pharmaceuticals的总裁;1998年至2003年间担任Synergy Pharmaceuticals的首席执行官,该公司已与Callisto Pharmaceuticals合并,而他在后者担任研发副总裁直至2006年。他领导研发卡铂(carboplatin)和顺铂(cisplatin)从概念到通过新药审核。这些药物一通过审核便被用于首选化疗药物。他获得了Brooklyn Polytechnic University的学士学位,1975年获得SUNY Albany的博士学位。
Donald Picker,has served as Cns Pharmaceuticals, Inc. part-time chief science officer since June 2019. Dr. Picker has served as the chief scientific officer of Moleculin Biotech, Inc. since August 2017 after serving as its chief operating officer from July 2015 until August 2017 and as its president from January 2016 to August 2017. In 2007, Dr. Picker became the chief executive officer of IntertechBio Corp. From 2006 through 2007, Dr. Picker was the President of Tapestry Pharmaceuticals. From 1998 to 2003, Dr. Picker was CEO of Synergy Pharmaceuticals. Synergy was merged into Callisto Pharmaceuticals where he was vice present of research and development until 2006. From 2017 to 2018, Dr. Picker served on Cns Pharmaceuticals, Inc. board of directors. Dr. Picker received his B.S. degree from Brooklyn Polytechnic University and his PhD from SUNY Albany in 1975. Dr. Picker is currently devoting only 25% of his work time to Cns Pharmaceuticals, Inc. and provides services as needed to Cns Pharmaceuticals, Inc. .
Robert Shepard

Robert Shepard自2016年6月以来一直担任我们的首席医疗官(兼职)。从2013年到2014年,谢泼德博士担任Accelovance的科学和医疗事务Vice President。Shepard博士在血液学和肿瘤学方面拥有广泛的研究证书,并在肿瘤学,血液学和内科获得董事会认证。他在转化医学和临床研究方面拥有广泛的经验,自1970年以来一直积极参与肿瘤学研究,负责生物制药公司的几种药物和免疫疗法的临床开发,包括担任六家公司的咨询首席医疗官。Shepard博士是哈佛大学(Harvard University)生化科学和分子生物物理学的优等生,并在哈佛-麻省理工学院(Harvard-M.I.T.Health Sciences Program)学习。他在Tufts-New England Medical Center获得血液学和肿瘤学研究金,在那里他进行白血病、骨髓瘤和骨髓增生异常的实验室研究,以及在Dana-Farber癌症中心和哈佛医学院获得药理学和分子遗传学研究金。Shepard博士在哈佛大学(Harvard University)、塔夫茨大学(Tufts University)和弗吉尼亚大学(University of Virginia)拥有学术任命。


Robert Shepard has served as our chief medical officer, on a part-time basis, since June 2016. From 2013 until 2014 Dr. Shepard served as vice president of scientific and medical affairs for Accelovance. Dr. Shepard has extensive research credentials in hematology and oncology and is board certified in oncology, hematology and internal medicine. He has a wide array of experience in translational medicine and clinical research and has been actively involved in oncology research since 1970 responsible for the clinical development of several drugs and immune therapies for biopharmaceutical companies. Dr. Shepard is a Magna Cum Laude graduate of Harvard University in biochemical sciences and molecular biophysics and studied in the Harvard-M.I.T. Health Sciences program. He held fellowships in hematology and oncology at the Tufts-New England Medical Center where he conducted laboratory research in leukemias, myeloma and myelodysplasia, as well as fellowship in pharmacology and molecular genetics at the Dana-Farber Cancer Center and Harvard Medical School. Dr. Shepard holds academic appointments at Harvard University, Tufts University and the University of Virginia.
Robert Shepard自2016年6月以来一直担任我们的首席医疗官(兼职)。从2013年到2014年,谢泼德博士担任Accelovance的科学和医疗事务Vice President。Shepard博士在血液学和肿瘤学方面拥有广泛的研究证书,并在肿瘤学,血液学和内科获得董事会认证。他在转化医学和临床研究方面拥有广泛的经验,自1970年以来一直积极参与肿瘤学研究,负责生物制药公司的几种药物和免疫疗法的临床开发,包括担任六家公司的咨询首席医疗官。Shepard博士是哈佛大学(Harvard University)生化科学和分子生物物理学的优等生,并在哈佛-麻省理工学院(Harvard-M.I.T.Health Sciences Program)学习。他在Tufts-New England Medical Center获得血液学和肿瘤学研究金,在那里他进行白血病、骨髓瘤和骨髓增生异常的实验室研究,以及在Dana-Farber癌症中心和哈佛医学院获得药理学和分子遗传学研究金。Shepard博士在哈佛大学(Harvard University)、塔夫茨大学(Tufts University)和弗吉尼亚大学(University of Virginia)拥有学术任命。
Robert Shepard has served as our chief medical officer, on a part-time basis, since June 2016. From 2013 until 2014 Dr. Shepard served as vice president of scientific and medical affairs for Accelovance. Dr. Shepard has extensive research credentials in hematology and oncology and is board certified in oncology, hematology and internal medicine. He has a wide array of experience in translational medicine and clinical research and has been actively involved in oncology research since 1970 responsible for the clinical development of several drugs and immune therapies for biopharmaceutical companies. Dr. Shepard is a Magna Cum Laude graduate of Harvard University in biochemical sciences and molecular biophysics and studied in the Harvard-M.I.T. Health Sciences program. He held fellowships in hematology and oncology at the Tufts-New England Medical Center where he conducted laboratory research in leukemias, myeloma and myelodysplasia, as well as fellowship in pharmacology and molecular genetics at the Dana-Farber Cancer Center and Harvard Medical School. Dr. Shepard holds academic appointments at Harvard University, Tufts University and the University of Virginia.
Sandra L. Silberman

Sandra L. Silberman于2017年12月加入CNS,目前兼职服务。她曾担任molecular Biotech, Inc.的新产品首席医疗官(2017年11月以来)。2018年,Silberman博士成为波兰WPD Pharmaceuticals的顾问。在Bristol Myers Squibb、AstraZeneca、Imclone和Roche等领先生物制药公司的工作期间,Silberman博士将几个原创、专有化合物推进到I期至III期。Silberman博士是一名血液学家/肿瘤学家,她获得了学士学位,理学学士学位。以及约翰霍普金斯大学文理学院、公共卫生学院和医学院的博士学位,以及Cornell University医学院的医学博士学位。之后在Brigham & Women医院和Dana Farber癌症研究所完成了血液学/肿瘤学的临床奖学金和肿瘤免疫学的研究奖学金。


Sandra L. Silberman,joined CNS in December 2017 and currently serves on a part-time basis. Dr. Silberman has served as chief medical officer for new products of Moleculin Biotech, Inc. since November 2017 on a part-time basis. Dr. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including BristolMyers Squibb, AstraZeneca, Imclone and Roche. Dr. Silberman is a Hematologist/Oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College, and then completed both a clinical fellowship in Hematology/Oncology as well as a research fellowship in tumor immunology at the Brigham & Women' s Hospital and the Dana Farber Cancer Institute in Boston, MA. Dr. Silberman is currently devoting only 45% of her work time to Cns Pharmaceuticals, Inc. and provides services as needed to Cns Pharmaceuticals, Inc. .
Sandra L. Silberman于2017年12月加入CNS,目前兼职服务。她曾担任molecular Biotech, Inc.的新产品首席医疗官(2017年11月以来)。2018年,Silberman博士成为波兰WPD Pharmaceuticals的顾问。在Bristol Myers Squibb、AstraZeneca、Imclone和Roche等领先生物制药公司的工作期间,Silberman博士将几个原创、专有化合物推进到I期至III期。Silberman博士是一名血液学家/肿瘤学家,她获得了学士学位,理学学士学位。以及约翰霍普金斯大学文理学院、公共卫生学院和医学院的博士学位,以及Cornell University医学院的医学博士学位。之后在Brigham & Women医院和Dana Farber癌症研究所完成了血液学/肿瘤学的临床奖学金和肿瘤免疫学的研究奖学金。
Sandra L. Silberman,joined CNS in December 2017 and currently serves on a part-time basis. Dr. Silberman has served as chief medical officer for new products of Moleculin Biotech, Inc. since November 2017 on a part-time basis. Dr. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including BristolMyers Squibb, AstraZeneca, Imclone and Roche. Dr. Silberman is a Hematologist/Oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College, and then completed both a clinical fellowship in Hematology/Oncology as well as a research fellowship in tumor immunology at the Brigham & Women' s Hospital and the Dana Farber Cancer Institute in Boston, MA. Dr. Silberman is currently devoting only 45% of her work time to Cns Pharmaceuticals, Inc. and provides services as needed to Cns Pharmaceuticals, Inc. .
Jonathan P. Foster

Jonathan P. Foster自2012年3月以来,担任公司的首席财务官。他在多家上市与非上市公司担任高级财务职位。从2011年到2012年,他担任德克萨斯州达拉斯LSG Sky Chefs USA的临时财务总监,LSG Lufthansa Service Holding AG的子公司,其总部设在德国。从2000年到2011年,他担任United Credit的大股东和总裁,以及另外两家公司- Advance Today and Furobos Reinsurance的创始人兼首席执行官,这两家公司主要从事消费金融和间接保护保险市场。从1996年到2000年,他Drypers集团的担任执行副总裁和首席财务官,一家全球消费品公司,目标市场主要是北美、南美、亚洲和欧洲。从1991年到1996年,他担任Dickson Weatherproof Nail 公司的首席财务官,一家私人公司,位于休斯顿和芝加哥。他担任Schlumberger公司的财务总监。他于1985年在Deloitte & Touche的企业集团开始他的会计生涯,该公司位于北卡罗莱纳的夏洛特。后来,他担任公司在格鲁吉亚的亚特兰大地区的中间市场集团经理。他是一名南卡罗来纳州的注册会计师和AIPCA的成员,他拥有全球特许管理会计师称号。他拥有克莱姆森大学会计学士学位。从2006年到2012年,他担任Easley Baptist Hospital Foundation董事会成员。从2006年到2012年,他也担任金融机构的董事会成员,负责国家特许银行和南卡罗来纳州的其他特许金融机构。


Jonathan P. Foster has served as our chief financial officer and executive vice president since August 2016. From February 2012 to August 2016 Mr. Foster served as Chief Financial Officer and Executive Vice President of InfuSystem Holdings, Inc., a national provider of infusion pumps and related services to the healthcare industry. From May 2011 to January 2012 Mr. Foster served as a consultant to the Chief Financial Officer of LSG Sky Chefs, USA, Inc., a subsidiary of Deutsche Lufthansa AG.Prior to that Mr. Foster served in various C-suite capacities with public and private companies with his start beginning as Manager at Deloitte & Touche, LLP. Mr. Foster served on the Board of Financial Institutions for the State of South Carolina from 2006 to 2012 and since June 2018 serves on the Board of Directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics, where he is the current chair of the Audit and Compensation Committees and is the past chair of the Nominating & Governance Committee. Mr. Foster is a Certified Public Accountant South Carolina and holds the designation of Chartered Global Management Accountant from the American Institute of Certified Public Accountants. He received his BS in Accounting from Clemson University in 1985.
Jonathan P. Foster自2012年3月以来,担任公司的首席财务官。他在多家上市与非上市公司担任高级财务职位。从2011年到2012年,他担任德克萨斯州达拉斯LSG Sky Chefs USA的临时财务总监,LSG Lufthansa Service Holding AG的子公司,其总部设在德国。从2000年到2011年,他担任United Credit的大股东和总裁,以及另外两家公司- Advance Today and Furobos Reinsurance的创始人兼首席执行官,这两家公司主要从事消费金融和间接保护保险市场。从1996年到2000年,他Drypers集团的担任执行副总裁和首席财务官,一家全球消费品公司,目标市场主要是北美、南美、亚洲和欧洲。从1991年到1996年,他担任Dickson Weatherproof Nail 公司的首席财务官,一家私人公司,位于休斯顿和芝加哥。他担任Schlumberger公司的财务总监。他于1985年在Deloitte & Touche的企业集团开始他的会计生涯,该公司位于北卡罗莱纳的夏洛特。后来,他担任公司在格鲁吉亚的亚特兰大地区的中间市场集团经理。他是一名南卡罗来纳州的注册会计师和AIPCA的成员,他拥有全球特许管理会计师称号。他拥有克莱姆森大学会计学士学位。从2006年到2012年,他担任Easley Baptist Hospital Foundation董事会成员。从2006年到2012年,他也担任金融机构的董事会成员,负责国家特许银行和南卡罗来纳州的其他特许金融机构。
Jonathan P. Foster has served as our chief financial officer and executive vice president since August 2016. From February 2012 to August 2016 Mr. Foster served as Chief Financial Officer and Executive Vice President of InfuSystem Holdings, Inc., a national provider of infusion pumps and related services to the healthcare industry. From May 2011 to January 2012 Mr. Foster served as a consultant to the Chief Financial Officer of LSG Sky Chefs, USA, Inc., a subsidiary of Deutsche Lufthansa AG.Prior to that Mr. Foster served in various C-suite capacities with public and private companies with his start beginning as Manager at Deloitte & Touche, LLP. Mr. Foster served on the Board of Financial Institutions for the State of South Carolina from 2006 to 2012 and since June 2018 serves on the Board of Directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics, where he is the current chair of the Audit and Compensation Committees and is the past chair of the Nominating & Governance Committee. Mr. Foster is a Certified Public Accountant South Carolina and holds the designation of Chartered Global Management Accountant from the American Institute of Certified Public Accountants. He received his BS in Accounting from Clemson University in 1985.